This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Idenix Pharmaceuticals' CEO Provides Update On IDX184 Clinical Development Program Conference (Transcript)

Stocks in this article: IDIX

Additional information concerning these factors is contained in our filings with the SEC today, which are available on our investor section of our website.

While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so even if our assumptions change.

You should not rely on these forward-looking statements as representing our assumptions as of any date subsequent to today. We issued a press release this morning and on today’s call, Ron will discuss the partial clinical hold based on IDX 184, and then we will open up the call up for Q&A. I'll now turn the call over to Ron.

Ron Renaud

Thanks Daniella. We were verbally notified by the FDA late yesterday afternoon that our clinical candidate IDX184 has been placed on partial clinical hold. We believe this is a result of the recent occurrence of a serious cardiac-related adverse event with Bristol-Myers BMS094 which is that company’s nucleotide pro-drug for the treatment of HCV.

The FDA has expressed an interest in further reviewing the safety of IDX184 and therefore it has placed IDX184 on partial clinical hold.

In previous clinical trials as well as the ongoing Phase IIb clinical trial of IDX184 dosed in combination with pegylated interferon and ribavirin, there has been no evidence to date of cardiotoxicity in patients dosed with IDX184 and pegylated interferon and ribavirin, beyond that seeing with pegylated interferon and ribavirin alone.

I should also add that there are no -- there are currently no patients receiving IDX184 worldwide. We believe and we assert that there are significant differences between IDX184 and BMS094, including an entirely different pro-drug approach.

In our view there at least three components of BMS094 and its metabolites that are not present in IDX184 and which could have contributed to the reported toxicity of BMS094.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs